VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

MIKE HENNESSY, SR.
Immunotherapy revolutionized the way we treat cancer. And now, researchers are using drugs to help jumpstart the immune system alongside chemotherapy to keep treatment moving forward.
 
DEBU TRIPATHY, M.D.
Lung cancer has gone from being a dismal diagnosis — it still is very serious — to one that is the poster child for targeted therapeutics, immunotherapy and molecular diagnostics. These advancements are just the beginning.
KATIE BROWN, OPN-CG
Unique challenges become permanent fixtures in the minds of young adults who receive a diagnosis of a life-changing disease, but can change through advocacy support.
Katie Kosko
During National Women’s Lung Health Week, a lung cancer survivor shares her story and success with targeted therapy.
Jason M. Broderick
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Tecentriq (atezolizumab) to be used in combination with Avastin (bevacizumab), carboplatin and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).
MEERI KIM, PH.D.
Second cancers are common among patients with lung cancer, so how can risk be lowered?
ARLENE WEINTRAUB
Immune and targeted therapies build hope for patients with advanced lung cancer.
TARA HAELLE
The combination of immunotherapy and chemotherapy, and more, is changing the landscape of the disease.
Jason M. Broderick
The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), according to Merck (MSD), the manufacturer of the PD-1 inhibitor. 
 
The Food and Drug Administration (FDA) approved Tagrisso as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable